DiPersio Recognized for Key Discoveries in Cancer Biology, Treatment
Siteman Cancer Center
John F. DiPersio, MD, PhD, director of the Division of Oncology at Washington University School of Medicine in St. Louis, is being recognized by the American Italian Cancer Foundation with the 2022 Prize for Scientific Excellence in Medicine.
Read More
Gardiner Receives ASCB Award
Fox Chase Cancer Center, Temple Health
Jaye Gardiner, PhD, has received the Merton Bernfield Memorial Award, established to honor outstanding postdocs or graduate students, from the American Society for Cell Biology. Her research focuses on the tumor microenvironment and the growth of tumors in pancreatic ductal adenocarcinoma.
Read More
Markey Earns Rectal Cancer Accreditation
UK Markey Cancer Center
UK Markey Cancer Center has earned a three-year accreditation from the National Accreditation Program for Rectal Cancer. UK Markey is one of around 60 centers in the nation and the first in Kentucky to hold this designation.
Read More
Back to News From the Centers
$710.5 Million Gift to Accelerate Cancer and Infectious Disease Research
Fred Hutch Cancer Center
The Bezos family has committed $710.5 million over the next decade to support Fred Hutchinson Cancer Center's efforts to dramatically accelerate medical breakthroughs in cancer and infectious disease. This is the second recent transformational Fred Hutch donor commitment; a gift of $78 million from Stuart and Molly Sloan was announced in September. Thomas J. Lynch Jr., MD, is the center's president and director.
Read More
$12 Million Grant Aimed at Study of Rare Sarcoma
University of Michigan Rogel Cancer Center
An international team of researchers led by the University of Michigan Rogel Cancer Center received a collaborative grant from the National Cancer Institute with a goal of bringing new insights into leiomyosarcoma, a rare form of cancer that seemingly originates in smooth muscle.
Read More
NCI Renews Lymphoma SPORE Grant for Center for Cell and Gene Therapy
Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine
The National Cancer Institute has awarded more than $10.3 million to continue translational lymphoma research at the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital, and Texas Children’s Hospital. The grant is awarded through the NCI’s Specialized Programs of Research Excellence (SPORE) funding, which was established to promote collaborative, interdisciplinary translational cancer research.
Read More
NCI Award to Establish Center to Improve Radiation-Based Combination Therapies
Winship Cancer Institute of Emory University
The National Cancer Institute recently awarded more than $7.9 million for a new Radiation Oncology-Biology Integration Network (ROBIN) center at Winship Cancer Institute and the Cleveland Clinic. The ROBIN Genomic-TME-Temporal Dynamics Center aims to uncover the genetic and environmental factors, as well as the timing and interactions, that influence the effectiveness of radiation-based combination therapies.
Read More
Etzioni Receives $7.4 Million NCI Grant to Assess New Cancer Diagnostics
Fred Hutch Cancer Center
Ruth Etzioni, PhD, has received a seven-year Outstanding Investigator Award from the National Cancer Institute. The award, which comes with around $7.4 million in funding, will allow Dr. Etzioni and her team to build frameworks and tools to evaluate novel cancer diagnostics such as new nuclear imaging modalities and multi-cancer early detection tests.
Read More
$6 Million Grant Supports Development of New NCI Prevention Initiative
Fox Chase Cancer Center, Temple Health
Fox Chase Cancer Center was recently awarded a grant for $6 million over the course of five years to develop a new Cancer Prevention-Interception Targeted Agent Discovery Program. The new National Cancer Institute (NCI) program was created to establish a pipeline for the discovery of new cancer-prevention agents.
Read More
Researcher to Study Barriers to Quitting Menthol Cigarettes Among African Americans
UAMS Winthrop P. Rockefeller Cancer Institute
Dina M. Jones, PhD, MPH, has received a grant to study disparities in smoking cessation among African American menthol cigarette smokers. The project seeks to understand why African American cigarette smokers—more than 85 percent of whom use menthol cigarettes—are less likely to quit smoking than white smokers and those who use non-menthol cigarettes.
Read More
Back to News From the Centers
Deputy AD for Diversity and Inclusion in Clinical Research Named
University of Colorado Cancer Center
As lead investigator or sub-investigator on numerous clinical trials at the University of Colorado Cancer Center Jessica McDermott, MD, has been instrumental in improving access to cancer clinical trials for patients from medically underserved communities. She will now bring her expertise in this area to her new role as deputy associate director for diversity and inclusion in clinical research.
Read More
New Director Named for Healthy Breast Tissue Bank
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
The Indiana University Melvin and Bren Simon Comprehensive Cancer Center has named Michele Coté, PhD, director of the Susan G. Komen Tissue Bank, the world’s only healthy breast tissue bank. She succeeds Anna Maria Storniolo, MD, a pioneering clinical scientist who co-founded the tissue bank in 2007.
Read More
Hyslop Returns as Cancer Risk and Control Program Co-Leader, Center for Health Equity Director
Sidney Kimmel Comprehensive Cancer Center at Jefferson
Sidney Kimmel Cancer Center (SKCC) welcomes transdisciplinary population health researcher Terry Hyslop, PhD, as co-leader of the Cancer Risk and Control Program. She will also head the newly formed SKCC Center for Health Equity. Dr. Hyslop is returning to the cancer center from Duke Cancer Institute.
Read More
Physician Scientist to Lead Breast Oncology Program
Cedars-Sinai Cancer
Yuan Yuan, MD, PhD, a breast medical oncologist and physician scientist who specializes in triple-negative breast cancer and breast cancer immunotherapy, has joined Cedars-Sinai Cancer as director of breast oncology. Dr. Yuan will also treat patients at Huntington Cancer Center, an affiliate of Cedars-Sinai Cancer.
Read More
Christopher Joins Cancer Care Teams
UMMC Cancer Center and Research Institute
The University of Mississippi Medical Center (UMMC) welcomes Wade Christopher, MD, who will be part of the UMMC Cancer Center and Research Institute's interdisciplinary liver and bile duct cancer care team and the gastrointestinal cancer care team. He’ll also work with patients with sarcoma, thyroid, and melanoma cancers.
Read More
Four New Oncologists Welcomed
UAMS Winthrop P. Rockefeller Cancer Institute
The addition of four new oncologists—Sonia T. Orcutt, MD; Cesar Giancarlo Gentille Sanchez, MD; Santanu Samanta, MD; and Anusha Jillella, MD—will expand services and increase access for patients at UAMS Winthrop P. Rockefeller Cancer Institute and its growing network of clinics at Baptist Health locations.
Read More
Lowery Named Assistant Director for Dissemination and Implementation
University of Colorado Cancer Center
Jan Lowery, PhD, MPH, who started her career as a researcher at the University of Colorado Cancer Center, has returned as assistant director for dissemination and implementation for the Office of Community Outreach and Engagement. In her new role, Dr. Lowery will lead efforts to develop, conduct, and disseminate implementation-focused projects in cancer prevention, early detection, and survivorship.
Read More
Radiation Oncologist Joins NYU Langone Health
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
NYU Langone Health has announced the appointment of physician and researcher Oren Cahlon, MD, as senior vice president and deputy chief clinical officer. Dr. Cahlon will also maintain a clinical practice within the Department of Radiation Oncology at Perlmutter Cancer Center.
Read More
New Endowed Chair and Fellowship Holders, and Renewed Endowed Chairs
Huntsman Cancer Institute at the University of Utah
Huntsman Cancer Institute announces the appointment of two researchers as holders of endowed chairs at the University of Utah. Another colleague was awarded a fellowship, and two other distinguished endowed chairs have been renewed.
Read More
Back to News From the Centers
Oncology Therapy at the End of Life: Have We Missed the Mark?
Yale Cancer Center, Yale School of Medicine
Over the last decade, major professional societies have recommended that clinicians decrease the use of systemic anti-cancer therapies at the end-of-life stage. In a new study, researchers at Yale Cancer Center, in collaboration with researchers from Flatiron Health, Inc., revealed that despite these recommendations, aggressive cancer care at the end of life persists and there has been a substantial transition from the use of chemotherapy to immunotherapy.
Read More
Policy, Resources Crucial for Lung Cancer Screening
Vanderbilt-Ingram Cancer Center
A Veterans Health Administration project that provided resources for lung cancer screening programs increased the number of veterans screened, according to a new study. The findings have already been used to advocate for a Department of Veterans Affairs National Lung Cancer Screening Program Office, which is now in place.
Read More
Researchers Identify Key Player in Cellular Response to Stress
Simmons Comprehensive Cancer Center, UT Southwestern Medical Center
An enzyme called Fic, whose biochemical role was discovered at UT Southwestern more than a dozen years ago, appears to play a crucial part in guiding the cellular response to stress, a new study suggests. The findings could eventually lead to new treatments for a variety of diseases.
Read More
A Novel Strategy to Suppress Prostate Cancer Growth
Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine
Finding valuable therapeutic interventions for prostate cancer has long guided the research of the lab of Feng Yang, PhD, at Baylor College of Medicine. In a new study, Dr. Yang’s team took a close look into what drives the growth of advanced tumors that have become resistant to standard castration therapy. Working with cells in the lab and animal models, they discovered an approach that suppresses the growth of therapy-resistant tumors.
Read More
Clinical Trial Begins to Help Black, Latina Women Concerned About Chemotherapy-Induced Hair Loss
Montefiore Einstein Comprehensive Cancer Center
A clinical trial now kicking off at Montefiore Einstein Cancer Center will test whether scalp cooling can protect Black and Latina women with textured hair types from hair loss due to chemotherapy, known as chemotherapy-induced alopecia (CIA). The trial will also determine which women are at high risk for permanently losing their hair due to CIA.
Read More
Researchers Find Link Between Immune Cells' Closest Neighbors and Survival Time in Patients With Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Researchers from Johns Hopkins Medicine have discovered that the organization of different types of immune cells within pancreatic tumors is associated with how well patients with pancreatic cancer respond to treatment and how long they survive. The new findings could eventually lead to new ways of treating pancreatic cancer.
Read More
Scientists Identify Unique Breast Cancer Cells That Control Their Ability to Proliferate and Colonize the Lungs
The Tisch Cancer Institute at Mount Sinai
Scientists from The Tisch Cancer Institute have uncovered a mechanism by which certain breast cancer cells regulate their own metastases, fuel dissemination from the original tumor site, and determine routes to invade distant organs such as the lungs.
Read More
CAR22 Therapy Granted Breakthrough Designation by FDA
Stanford Cancer Institute
Stanford Cancer Institute members Matthew Frank, MD, PhD, and David Miklos, MD, PhD, have received FDA breakthrough therapy designation on a trial using CAR22 to treat patients with relapsed/refractory large B-cell lymphoma that has progressed after prior CAR19 therapy.
Read More
Study Reveals Pathways for Aggressive Prostate Cancer Subtype
Vanderbilt-Ingram Cancer Center
Cribriform prostate cancer is an aggressive subtype of the disease characterized by its histology, but little is known about its molecular pathways. Research from Vanderbilt-Ingram Cancer Center has revealed new information about these pathways, including potential therapies.
Read More
Experimental Test Promises to Predict Side Effects, Return of Cancer in Patients Treated With Immunotherapy
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
A new study, led by researchers at NYU Grossman School of Medicine and NYU Langone Health’s Perlmutter Cancer Center, has generated data suggesting that a newly identified panel of autoantibodies, if found in patients’ blood before immunotherapy, has the potential to accurately predict whether cancer would recur for a patient and if they would experience autoimmune side effects because of the treatment itself.
Read More
Study Provides New Insights on Improving Immunotherapy Efficacy
Winship Cancer Institute of Emory University
The combination of an immunotherapy, PD-1 blockade, and biologic therapy, IL-2 therapy, generate higher quality effector CD8+ T cells which resemble the highly functional effector CD8+ T cells seen after acute viral infection that help the immune system control or clear the virus.
Read More
Survey Finds Most Women Unaware of Signs of Aggressive Form of Breast Cancer
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
A new national survey commissioned by The Ohio State University Comprehensive Cancer Center – The James found that most women are unaware of the unusual symptoms of a particularly aggressive and deadly form of the disease known as inflammatory breast cancer.
Read More
Researchers Create New Cancer Fighting Compound
UK Markey Cancer Center
A UK Markey Cancer Center researcher’s team developed new chemical compounds that show promise as a potential anticancer therapy to treat aggressive tumors. The new gold-derived compounds were toxic to cancer cells but well-tolerated by mice, giving them potential in the development of new cancer drugs.
Read More
Researchers Develop 'Goldilocks' Drug to Treat Triple-Negative Breast Cancer
The University of Arizona Cancer Center
A team of University of Arizona researchers have developed a drug compound that appears to stop cancer cell growth in triple-negative breast cancer. The drug, which has not yet been tested in humans, has been shown to eliminate tumors in mice, with little to no effect on normal healthy cells, making it potentially nontoxic for patients.
Read More
Researchers Discover New Molecular Driver of Retinoblastoma
Simmons Comprehensive Cancer Center, UT Southwestern Medical Center
Researchers at UT Southwestern and the University of Miami have discovered that a molecule—estrogen-related receptor gamma, or ESRRG—becomes hyperactive and promotes tumor cell survival in retinoblastoma. Blocking ESRRG, the team reported, kills retinoblastoma cells.
Read More
Scientists Are One Step Closer to Stopping Drug-Resistant Tumors From Growing
Huntsman Cancer Institute at the University of Utah
Scientists have solved a long-standing mystery surrounding a cancer-promoting protein and how it causes tumor growth. The findings are an important step in the quest to make cancer drugs more effective since aggressive tumors often become adept at resisting drugs and other therapeutic agents.
Read More
Back to News From the Centers
UCSF Hosts First Lady Jill Biden to Discuss Breast Cancer Research
UCSF Helen Diller Family Comprehensive Cancer Center
First Lady Jill Biden, PhD, met with top UC San Francisco cancer leaders to hear about UCSF’s breast cancer research and progress on the National Cancer Moonshot. The visit highlighted the complexities of cancer, as well as UCSF advances in breast cancer research and programs that support breast cancer patients, survivors, and caregivers.
Read More
Scholars Converge to Accelerate Cancer Science
Cedars-Sinai Cancer
The Convergent Science Virtual Cancer Center, a program designed to train the next generation of cancer researchers, held its first in-person workshop for its first class of scholars. The program, led by Cedars-Sinai Cancer and the University of Southern California, is funded by an inaugural grant from the Department of Defense. Dan Theodorescu, MD, PhD, is director of Cedars-Sinai Cancer.
Read More
Cancer Center Joins Exclusive Clinical Trials Network
The University of Kansas Cancer Center
The University of Kansas Cancer Center is now a member of the National Cancer Institute’s Experimental Therapeutics Clinical Trials Network (ETCTN) as part of a consortium led by Yale Cancer Center. ETCTN membership will increase the number of early-stage clinical trials the cancer center can offer to people with cancer.
Read More
New International Collaboration Established to Reduce Women's Cancers
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center and World Health Organization have announced a formal agreement to establish a new international collaboration concentrated on reducing the global burden of women’s cancers.
Read More
Rogel Teams With Tobacco Quitline to Stem Menthol Use
University of Michigan Rogel Cancer Center
In Michigan, 40 percent of callers to the state’s Tobacco Quitline are menthol users. Now, a new partnership between the University of Michigan Rogel Cancer Center and the Quitline will develop and test strategies to help menthol users kick the habit.
Read More
Allison Institute Establishes Internal Advisory Council of Experts
The University of Texas MD Anderson Cancer Center
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center has announced the establishment of its internal advisory council to provide scientific input and to align the work of the institute with the broader MD Anderson research enterprise.
Read More
500th CAR T-cell Infusion
Stanford Cancer Institute
Stanford Health Care’s Blood and Marrow Transplantation & Cellular Therapy program performed its 500th Chimeric Antigen Receptor T-cell (CAR T) therapy infusion in September. The multi-disciplinary team—physicians, fellows, advanced practice providers, nurses, pharmacists, social workers, case management, clinic staff, and administrators—celebrated the milestone together.
Read More
Education and Outreach Home Under Construction
Roswell Park Comprehensive Cancer Center
Roswell Park Comprehensive Cancer Center is proud to break ground on a new Community Outreach and Engagement (COE) building. The project, which includes preservation of a home in Buffalo’s historic Fruit Belt neighborhood, will be the new home for the cancer center’s extensive COE team.
Read More
Back to News From the Centers